The Future of IBS:
Expert Panel on Digital Hypnotherapy RCT
Date
Tuesday 27 August, 4pm PDT
(West Coast US/Canadian practitioners)
Tuesday 27 August, 7pm EDT
(East Coast US/Canadian practitioners)
Wednesday 28 August, 9am AEST
(Australian practitioners)
*Can't make it live? Register to receive the recording.
About
Join us for a panel discussion with world-renowned IBS experts as they explore the results of a new randomized controlled trial (RCT) on managing IBS through digital hypnotherapy.
Lead author Ellie Anderson will present the study's findings. Following this, Dr. Simone Peters will be joined by Dr. Prashant Singh, Dr. Megan Riehl, and Beth Rosen to discuss the implications and practical application of the results.
A Q&A will follow the panel discussion.
They will discuss:
- The transformative impact of digital therapeutics on IBS pain management.
- The efficacy of app-delivered gut-directed hypnotherapy for improving symptom severity.
- Practical steps for clinicians to integrate digital hypnotherapy into care plans to improve patient quality of life.
- How the research supports a non-pharmacological approach to alleviating IBS-related psychological symptoms.
Meet the experts
Select speaker to read bio
“While I’ve been aware of gut-directed hypnotherapy for many years, I was happy to stumble across the Nerva app as it’s so hard for patients to receive in-person therapy like this because it’s expensive, waiting lists are long, and often patients need help much quicker.”
– Dr. Shamistra Barathan, GP, Mint Clinic
Save your spot
Visit Nerva for Clinicians to learn more about referring gut-directed hypnotherapy.
© Copyright 2024 Mindset Health Pty Ltd Terms & Conditions Privacy Policy
Anderson, E. J., Peters, S. L., Gibson, P. R., & Halmos, E. P. (2024). Comparison of digitally-delivered gut-directed hypnotherapy program to an active control for irritable bowel syndrome. The American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000002921
*Disclaimer: Nerva is a self-guided program that may help people self-manage and live well with their diagnosed irritable bowel syndrome. Nerva has not been evaluated by the FDA, TGA, MHRA or similar regulatory bodies. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.
